Close
CDMO Safety Testing 2026
Novotech

Rentschler Biopharma and Vetter Unveil Xpert Alliance

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...
- Advertisement -

Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), announced that the companies are unveiling Xpert Alliance, a joint visualization of their strategic collaboration. The visualization is designed to โ€œbring to lifeโ€ this ongoing alliance and celebrate its successful operation, delivering effective solutions to address clientsโ€™ changing and expanding needs in the area of complex biopharmaceuticals.

In mid-2020, Vetter and Rentschler Biopharma entered this strategic alliance intended to create long-term value that enables clients to bring their complex products to patients more easily and faster, through the coordination of their respective manufacturing services. By offering complementary skills and experience along the biopharmaceutical value chain, together, the two CDMOs have mutually enhanced their services, evidenced by the strong progress in their ongoing initial joint client projects. Since that time, the two independent companies have worked closely together to advance this important alliance. Todayโ€™s announcement marks an important step in heightening the visibility of the collaborative services to clients, as the strategic alliance matures.

โ€œIt is exciting to see how our alliance has been steadily evolving and taking shape,โ€ stated Dr. Frank Mathias, CEO of Rentschler Biopharma. โ€œWe and Vetter have ambitious goals for our collaboration and believe that our clients can greatly benefit from the complementary services and seamless interactions we offer, with the ultimate aim of bringing new, life-changing treatment options to patients.โ€

Vetter Managing Director Peter Soelkner agreed: โ€œWith joint projects ongoing, the day-to-day workings of our strategic alliance are running smoothly, as we work together to create best-in-class solutions for our clients from early development stage through to the market. We are pleased with the progress we have made so far and look forward to demonstrating the added value we are generating through our collaboration.โ€

Xpert Alliance, the name of the joint visualization introduced today, clearly indicates what this strategic collaboration of two leading CDMOs can offer, and the tagline โ€“ from substance to product to patient โ€“ outlines the breadth of the offering. The coming together of Rentschler Biopharma and Vetter is visually represented by the two shades of blue in the X โ€“ each of the companyโ€™s corporate colors. At the same time, the companies retain their individuality, as shown by the two names as part of the joint logo.

Xpert Alliance embodies the true essence of this important collaboration, and the visualization marks another milestone in this strong and growing partnership.

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...

Avenda Health Expands Unfold AI Into Midwest Cancer Care

Avenda Health said the University of Michigan Health Weiser...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป